Beauty (NYSE:ELF) reported first-quarter fiscal 2027 results on August 5, and the headline number is hard to ignore.

Cramer’s thoughts about Alphabet Inc. (NASDAQ:GOOGL) tie into the broader debate about the firm. As is the case with all big ...

Jim Cramer has consistently recommended buying cybersecurity stocks for more than a year. Two firms that regularly cross his ...

On August 5, IonQ (NYSE:IONQ) delivered the strongest quarter in its history, yet the stock still trades well below where it ...

TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the ‘TCW Concentrated Large ...

UGI (NYSE:UGI) walked into its fiscal 2026 third-quarter earnings call on August 6 with a split story to tell.

The World Health Organization projects that the share of the world’s population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the ...

AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The ...

HCA Healthcare, Inc. (NYSE:HCA) reported its second-quarter 2026 financial results on July 24, confirming the figures previewed earlier in the month. While top-line growth remained healthy, a visible ...

Pre-earnings options volume in e.l.f Beauty, Inc. (NYSE:ELF) traded at 1.2x normal levels on August 5, with calls leading puts 8:7. Implied volatility suggested traders were anticipating a ...

On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20).

Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn’t always competing head-to-head; it is ...